NextFin News - Cerba Healthcare, the French clinical laboratory giant backed by Swedish private equity firm EQT, has formally updated its lenders on a timeline to overhaul its €5 billion debt pile, signaling a critical juncture for one of Europe’s most leveraged healthcare credits. According to Bloomberg, the company held a call with creditors on Wednesday to outline a path toward restructuring its balance sheet, which has been strained by a combination of aggressive acquisition-led growth and a sharp contraction in margins following French regulatory price cuts.
The restructuring proposal involves a roughly €300 million equity injection from EQT in exchange for a 25% haircut on senior secured debt, according to data from Octus. This move follows a period of intense financial pressure where Cerba’s leverage reached a staggering 14.1 times EBITDA before adjustments in late 2025. The company had already fully drawn its €450 million revolving credit facility by the end of the third quarter of 2025, leaving it with minimal cash buffers and necessitating a €100 million emergency liquidity injection from EQT in November.
The current plan aims to address a "labyrinth" of financial instruments, including a €1.875 billion term loan due in 2028 and various senior secured and unsecured notes. Analysts at Ainvest have noted that Cerba’s 2028 senior notes carry covenant triggers at 6.5 times leverage, a threshold the company is currently far exceeding. While EQT’s willingness to provide fresh capital suggests a commitment to the asset, the proposed 25% haircut indicates that lenders will be forced to absorb significant losses to make the capital structure sustainable.
The laboratory sector in France has faced a perfect storm. During the pandemic, firms like Cerba and its rival Biogroup reaped massive profits from Covid-19 testing, which fueled a debt-backed acquisition spree. However, the French government has since aggressively cut reimbursement rates for routine medical tests to rein in healthcare spending. These regulatory headwinds have eroded EBITDA margins across the industry, turning what was once considered a stable, "infrastructure-like" healthcare business into a distressed credit story.
Some market participants remain skeptical of the current proposal's sufficiency. Analysts at Iason Ltd have questioned how leverage can be brought down meaningfully when gross debt has ballooned from €3.8 billion in 2021 to €5 billion today, while core earnings have failed to keep pace. This perspective suggests that the €300 million equity contribution might be a "band-aid" rather than a permanent fix, especially if further regulatory price cuts are enacted by French authorities in the coming budget cycles.
The outcome of these negotiations will serve as a bellwether for the broader European leveraged finance market, particularly for private equity-owned assets that were loaded with debt during the era of low interest rates. If EQT successfully pushes through the haircut with limited lender resistance, it may provide a template for other distressed healthcare providers. Conversely, a protracted battle with the steering committee of creditors could lead to a more coercive restructuring or a change in control, testing the limits of sponsor support in a high-rate environment.
Explore more exclusive insights at nextfin.ai.
